Abterra Bio News

Stay updated on all things Abterra Bio. Includes scientific and company updates.

New Service: Alicanto for Antibody Discovery from Human Serum

We recently had the pleasure of attending the PEGS Boston Conference. We had the privilege of showcasing our work through a poster presentation, a talk, and an exhibit booth. Among the highlights were engaging with experts, exchanging ideas, and strengthening our network within the community. But perhaps the most important was launching our newest service: Alicanto For Antibody Discovery From Human Serum. It was truly a great time for Abterra Biosciences!

Watch our CEO, Dr. Natalie Castellana’s presentation on Discovering SARS-CoV2 Antibodies From Patient Serum With Alicanto below. This was our first antibody discovery project utilizing human serum!

Click below to watch the presentation.

 

Related Posts

Abterra Opens Its Doors To Celebrate New Location With Open House

Abterra Opens Its Doors To Celebrate New Location With Open House

Abterra Opens Its Doors To Celebrate New Location With Open HouseCelebrating milestones is an important part of our personal and professional journeys. We wanted to commemorate this exciting new chapter in Abterra's story with the people who mean the most to us: our...

Case Study: Reptor Phage Enrichment

Case Study: Reptor Phage Enrichment

Case Study: Phage EnrichmentProject Summary: Phage display is a powerful toolkit for antibody discovery and engineering. In this study, we used phage display to identify Cas9-binding single domain (VHH) antibodies. In addition to traditional colony picking, we used...

Abterra Biosciences is a unique CRO offering antibody sequencing and discovery services.  We bring sophisticated algorithmic and machine learning approaches to enable accurate antibody sequencing and functional antibody discovery.

Tell Us About Your Project

Follow Abterra Bio On Social Media

More From Our Blog

Get In Touch

Tell Us About Your Project.

Need more information? We’re here to answer any questions you have.